Pasar al contenido principal

SENESCENCIA Y PLASTICIDAD CELULAR.

PID2021-122600OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence

  • Flores, Natalia García
  • Fernández-Aroca, Diego M.
  • Garnés-García, Cristina
  • Domínguez-Calvo, Andrés
  • Jiménez-Suárez, Jaime
  • Sabater, Sebastià
  • Fernández-Aroca, Pablo
  • Andrés, Ignacio
  • Cimas, Francisco J.
  • de Cárcer, Guillermo
  • Belandia, Borja
  • Palmero, Ignacio
  • Huertas, Pablo
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
Pan-cyclin-dependent-kinase (CDK) inhibitors are a new class of targeted therapies that can act on multiple CDKs, with dinaciclib being one of the most promising compounds. Although used as a monotherapy, an interesting approach could be to combine it with radiotherapy. Here, we show that dinaciclib increases radiosensitivity in some experimental models of lung and colon cancer (A549 or HCT 116) but not in others (H1299 or HT-29). Dinaciclib did not alter serine-protein kinase ATM signalling or cell cycle profiling after ionising-radiation exposure, which have been described for other CDK inhibitors. Interestingly, in terms of apoptosis, although the combination renders a clear increase, no potentiation of the ionising-radiation-induced apoptosis was observed. Mechanistically, inhibition of CDK12 by dinaciclib diminishes BRCA1 expression, which decreases homologous recombination (HR) and probably promotes the nonhomologous end joining repair process (NHEJ), which ultimately promotes the induction of ionising-radiation-associated cellular senescence in a TP53-dependent manner, explaining the lack of effect observed in some experimental models. In conclusion, our report proposes a molecular mechanism, based on the signalling axis CDK12-BRCA1, involved in this newly identified therapeutic effect of dinaciclib, although other players implicated in HR should not be discarded. In addition, our data provide a rationale for more selective and personalised chemo/radiotherapy treatment according to the genetic background of the tumour., We appreciate the technical assistance of SIB at IB, core facilities of IIB and the staff from the Radiotherapy Unit at the General Universitary Hospital of Albacete This work has been supported by grant PID2021-122222OB-I00 and PID2021-122600OB-I00 funded by MCIN/AEI/10.13039/501100011033/ and by Europena Regional Development Fund (FEDER) A way to make Europe and grant to RS-P and IP. S2022/BMD-7393 funded by Regional Government of Madrid to IP. PH lab is funded by grant PID2022-136791NB-I00 from MICIU/AEI/10.13039/501100011033/FEDER/UE. RS-P is also funded by UCLM with grant 2022-GRIN-34150 and by Agencia de Investigación e Innovación, Junta de Comunidades de Castilla-La Mancha grant SBPLY/23/180225/000007. FJC is funded by contracts for postdoctoral researchers for scientific excellence in the development of the Plan Propio I + D + i, co-financed by the European Social Fund Plus (ESF+). NGF is funded by ‘Investigo Programme’, for hiring young job seekers to carry out research and innovation initiatives, within the framework of the Recovery, Transformation and Resilience Plan – financed by the European Union – Next Generation EU, called by Order 190/2021, of 22 December, of the Regional Ministry of Economy, Business and Employment of the Regional Government of Castilla-La Mancha. JJ-S is funded by ‘Contrato predoctoral para la formación de personal investigador en el marco del plan propio de I + D + I UCLM 2020-PREDUCLM-15144’, co-financed by the European Social Fund Plus (ESF+). AD-C is funded with FPU fellowships from the Ministerio de Educación, Formación Profesional y Deportes (Lpb23). We are grateful for the funds contributed by Fundacion Leticia Castillejo and by the participants in the crowdfunding project ‘Irradiando Esperanza’, in particular to: Taller Solidario Árbol De La Vida (Las Pedroñeras), Asociación Comarcal Contra El Cáncer De Motilla Del Palancar, asociación Jareña Contra el Cancer Junta local contra el cáncer de Casimarro, and ACEPAIN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMOylation of the lysine-less tumor suppressor p14ARF counters ubiquitylation-dependent degradation

  • El Motiam, Ahmed
  • Bouzaher, Yanis H
  • Chen, Haifen
  • Seoane, Rocío
  • Vidal, Santiago
  • Blanquer, María
  • Tolosa, Rocío M
  • Rodríguez-Lemus, Beatriz
  • Herrera-Gavilán, José A
  • Vidal, Anxo
  • Palmero, Ignacio
  • Rodríguez, Manuel S.
  • Sutherland, James D
  • Barrio, Rosa
  • Xirodimas, Dimitris
  • Collado, Manuel
  • Bremner, Rod
  • Rivas, Carmen
p14ARF is a lysine-less tumor suppressor that enhances SUMOylation of its interactors. Although p14ARF is known to interact with the E2 SUMO conjugating enzyme UBC9, the link between ARF and SUMOylation is poorly understood and the potential impact of SUMOylation on p14ARF is unknown. Here we show that SUMO2 conjugates to the N-terminus of p14ARF and stabilizes it. Either depleting UBC9 or pharmacologically inhibiting SUMOylation, induces p14ARF degradation. In contrast, blocking ubiquitination or NEDDylation, with TAK-243 or MLN4924/Pevonedistat respectively, increases p14ARF SUMOylation and restores p14ARF levels when SUMOylation is blocked. Treatment with MLN4924 also causes p14ARF-dependent mRNA upregulation of the SUMOylation components SUMO1, SUMO2, and UBC9, globally augmenting SUMOylation. Finally, p14ARF contributes to MLN4924-driven cytotoxicity of prostate cancer cells. Our results provide evidence that, despite lacking lysine, p14ARF is SUMOylated and this modification is critical to counter ubiquitin driven degradation and establishes a new link between inhibition of NEDDylation and SUMOylation., Funding at the laboratory of CR is provided by Ministry of Science, Innovation and Universities and FEDER (PID2021-126510NB-I00), and Xunta de Galicia/ FEDER “Una manera de hacer Europa” (ED431G 2023/10). MB is a predoctoral fellow funded by Banco Santander and University of Santiago de Compostela. RMT is a predoctoral fellow funded by Instituto de Investigación Sanitaria de Santiago de Compostela. BRL is a predoctoral fellow funded by Asociación Española Contra el Cáncer (AECC). JAHG is funded by FPU grant from Ministry of Science and Innovation (MCIN), Spain (FPU23/00271). CR, MSR, JDC, DX, and RB acknowledge COST Action ProteoCure CA20113. RB and JDS acknowledge MCIN/AEI/10.13039/501100011033 (projects PID2023-147399NB-I00 and PID2020-114178GB-I00). IP lab is funded by PID2021-122600OB-I0., Peer reviewed